Approval · Notice of Compliance 38315 · 2026
PAXIL: Notice of Compliance 38315
Issued September 17, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38315
- Date
- September 17, 2026
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving production of the starting material. Change in the manufacturing process for the starting material
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAXIL | Not yet assigned | — |
Medicinal ingredients
- PAROXETINE HYDROCHLORIDE 20 MG per TAB